Goldenrod

What is Goldenrod?

The European Medicines Agency's only goldenrod monograph, adopted on September 4, 2008, covers one species, Solidago virgaurea, and classes it as a traditional remedy for minor urinary complaints. The goldenrod in some leading American products is a different species, and that gap runs through everything below.

Goldenrod is the common name for the genus Solidago in the daisy family (Asteraceae), a genus that a 2020 review in Biomolecules (Fursenco and colleagues) put at about 190 accepted species and infraspecific taxa, with roughly 330 more of uncertain status. Three matter commercially. European goldenrod (S. virgaurea) is native to Europe and Asia and is the species behind the European regulatory documents and most of the clinical record. Canadian goldenrod (S. canadensis) and giant or late goldenrod (S. gigantea, formerly S. serotina) are native to North America and have become invasive in several European countries, where they are also harvested as medicine. All three are tall perennials with plumes of small yellow flower heads in late summer and autumn, and the medicinal part is the dried flowering top. The genus name is usually traced to the Latin solidare, "to make whole," a nod to the plant's old use on wounds.

In Germany and Poland goldenrod is a licensed medicine sold in pharmacies as capsules, tablets, drops and tea for "flushing" the urinary tract. In the United States it is a dietary supplement, sold as cut herb and alcohol tinctures among other forms, with no federal review of the species, the dose or the claim.

Common Names

Goldenrod, European goldenrod, woundwort (S. virgaurea); Canadian goldenrod (S. canadensis); giant goldenrod, late goldenrod, smooth goldenrod (S. gigantea). Pharmacopoeial Latin: Solidaginis virgaureae herba for European goldenrod, and Solidaginis herba for the giant and Canadian species. German labels separate "Echtes Goldrutenkraut" (true goldenrod herb, S. virgaurea) from plain "Goldrutenkraut" (the North American species and their hybrids). French: verge d'or. "Rayless goldenrod" (Isocoma pluriflora), a toxic rangeland plant of the US Southwest, belongs to a different genus and is not sold as a supplement.

Primary Active Compounds

The German medpharm monograph collection (2003) gives these ranges for European goldenrod herb: flavonoids 1.1% to 2%, with rutin the main one at about 0.8%; triterpene saponins of the oleanane type (virgaureasaponins) at 0.2% to 0.3%; phenolic glycosides at 0.2% to 1.0%, led by leiocarposide (0.2% to 1%) with virgaureoside A at 0.01% to 0.14%; caffeic acid derivatives including chlorogenic acid at 0.2% to 0.4%; salicylic acid at about 0.1%; polysaccharides at 6% to 8%; and essential oil at 0.4% to 0.5%, falling below 0.2% in stored herb. The EMA's 2008 assessment report cites flavonoids at about 1.5%, saponins up to 2% and leiocarposide at 0.08% to 0.48%. The giant and Canadian species are held to a higher flavonoid minimum in the European Pharmacopoeia (see Forms & Standardization) and, according to the same EMA report, contain no leiocarposide at all.

Key Note

Leiocarposide, the phenolic glycoside most often credited with European goldenrod's diuretic and anti-inflammatory activity in rats, is "completely absent in Solidago canadensis L. and Solidago gigantea Ait.," in the words of the EMA assessment report. A product made from either North American species is chemically a different herb from the one the European monograph describes.

Goldenrod is a traditional European urinary herb with one species-specific approval, a record of open observational studies, and a single double-blind, placebo-controlled urinary trial, in which it was one of three ingredients.

Scan any Goldenrod product in seconds with the free NutrientWise app: App Store · Google Play

Primary Functions & Benefits

Goldenrod is sold for one job above all: making more urine so that the bladder and urethra are flushed more often.

What "irrigation of the urinary tract" means

German regulators call it Durchspülungstherapie, flushing therapy. The idea is mechanical: a mild increase in urine output, plus a deliberate high fluid intake, dilutes the urine and rinses bacteria and small crystals out of the lower tract before they settle. The German product leaflets reviewed for this issue pair the herb with a fluid instruction (1.5 to 2 liters a day for Cystinol long; at least 2 liters for the three-herb tablet Aqualibra), and the EMA monograph says "ensure appropriate fluid intake." It is not an antibiotic treatment, it does not sterilize urine, and the EMA wording makes it an adjuvant: something added to proper care for minor complaints, with instructions to see a doctor for fever, painful urination, spasms or blood in the urine. German labels add a 5-day limit before a doctor should be seen if symptoms persist.

Urine volume in people

The direct human evidence that goldenrod increases urine output is thin. The EMA assessment report describes one open, post-marketing crossover study with placebo in 22 healthy adults aged 17 to 61 (Bioforce AG, study 23223.P1, 1992, an unpublished company study) in which an ethanolic fresh-plant extract of S. virgaurea, Goldruten Tropfen, at 100 drops a day for 2 days raised daily urine volume by 27% (p < 0.01). The only other human diuresis result in the report comes from Fitolizyna, a Polish multi-herb paste, tested openly in 20 stone patients in 1960.

Irritable bladder and painful urination

Three open, uncontrolled post-marketing studies make up most of the clinical file. Schmitt (TW Urologie Nephrologie, 1996) gave an S. virgaurea dry extract (5.4:1, sold as Stromic) at 380 mg three times daily for 14 days to women with dysuria, and reported fewer trips to the toilet in 69.2%; the EMA assessment report records the cohort as 745 women aged 12 to 94, while the 2020 Biomolecules review gives it as 74, a tenfold discrepancy this issue could not resolve. Laszig and colleagues (Drogenreport, 1999) followed 1,487 patients with urinary infection, irritable bladder or stones taking Cystinol long capsules, 424.8 mg of a 5.0 to 7.1:1 dry extract in 30% ethanol three times daily for about 4 weeks, and physicians rated 79% improved on a global scale. Pfannkuch and Stammwitz (Zeitschrift für Phytotherapie, 2002) reported the 512 patients with chronic recurrent irritable bladder from that program separately: 96% improved over 5 weeks on the physicians' global rating. None had a control group, so none can separate the herb from time, extra fluid and the natural waxing and waning of bladder symptoms.

Urinary tract infection, as one ingredient of three

The strongest trial involving goldenrod tested Aqualibra (Medice, Germany), each tablet holding water extracts of restharrow root (80 mg), Java tea leaf (Orthosiphon, 90 mg) and goldenrod herb (180 mg, 4 to 7:1). Between October 1991 and March 1992, 200 women aged 18 to 75 with acute uncomplicated lower urinary tract infection were randomized to two tablets three times daily or placebo for 7 days, double-blind. The primary endpoint was bacterial, and it was analyzed only in the 122 women with usable urine cultures: 64.4% responded on the herbs against 25.4% on placebo (p < 0.0001). A 2019 reanalysis (Vahlensieck and colleagues, Antibiotics) found that in those 122, 15.3% of the herbal group needed an antibiotic during the study against 49.2% on placebo, and that symptom scores separated from day 1; the antibiotic difference remained significant across all 200 (p = 0.0248). The German product information does not name the goldenrod species, and the trial cannot say what goldenrod contributed.

Other combination studies

Cai and colleagues (World Journal of Urology, 2014) randomized 83 patients with long-term urinary catheters to a goldenrod, Java tea, birch and cranberry tablet once daily for 30 days or no treatment; among the 73 who finished, 10 of 43 treated patients and 16 of 30 controls had positive urine cultures (p = 0.013). Frumenzio and colleagues (2013) compared, retrospectively and without randomization, 107 women taking a goldenrod, Java tea and birch product with antibiotic prophylaxis against 57 on prophylaxis alone; relapse rates during treatment were the same (11.21% and 10.52%), though the authors reported a 2.5-fold higher relapse risk in the year after prophylaxis among women who had not taken the herbs. In 2026 Gallo and colleagues (Urologia) randomized 60 patients with ureteral stents to tamsulosin 0.4 mg or a five-herb capsule containing goldenrod for a month, open label; tamsulosin did better on the urinary symptom domain at days 7 and 21, with no difference on pain or general health.

Rheumatic pain, in a fixed combination

Phytodolor (STW1, Steigerwald, Germany) is an alcoholic extract of fresh aspen, ash bark and goldenrod in a 60 to 20 to 20 volume ratio, licensed in Germany for painful rheumatic conditions and tested in several placebo-controlled and NSAID-controlled trials, many unpublished, according to a 2020 review that drew partly on the manufacturer's registration reports (Gundermann and colleagues). Goldenrod is one fifth of the mixture, and no trial isolates its share.

Antimicrobial and anti-inflammatory claims

These rest on laboratory work. An S. virgaurea extract slowed the growth of uropathogenic E. coli in culture and reduced biofilm at 24 hours, but not at 48 (Wojnicz and colleagues, Pharmaceutics, 2021), and saponin fractions inhibit Candida species. In rats, a commercial giant goldenrod extract, Urol mono, matched diclofenac against paw edema at a high dose (Leuschner, Arzneimittel-Forschung, 1995). In a double-blind trial of 66 healthy adults, a fluoride toothpaste containing an S. virgaurea extract lowered plaque bacterial load over 4 weeks, while plaque and gum indices improved in both groups (Prêcheur and colleagues, Antibiotics, 2020), a dental result, not a swallowed one.

Forms & Standardization

Two questions decide what a goldenrod product is: which species, and which preparation. The European system answers both on the label. The US market often answers neither.

Two pharmacopoeial herbs, not one

The European Pharmacopoeia carries two separate monographs. European goldenrod (Solidaginis virgaureae herba) is the dried flowering aerial parts of S. virgaurea, with total flavonoids of at least 0.5% and at most 1.5%, expressed as hyperoside. Goldenrod (Solidaginis herba) is the dried flowering aerial parts of S. gigantea or S. canadensis, with total flavonoids of not less than 2.5%, expressed as hyperoside. The ceiling on the European species and the higher floor on the North American ones reflect differences between the species rather than a single quality scale. "Expressed as hyperoside" means a total flavonoid assay calibrated against hyperoside, not a measurement of hyperoside itself. When Zekič and colleagues (Forests, 2021) measured individual flavonoids in their samples, Canadian goldenrod held 27.62 mg/g rutin and only 0.80 mg/g hyperoside, while giant goldenrod held 1.67 mg/g rutin, 7.63 mg/g hyperoside and 6.61 mg/g quercitrin, which was below detection in the Canadian sample.

What the EMA monograph allows

The 2008 monograph covers only S. virgaurea and lists four preparations: comminuted (cut) herb for tea; a liquid extract at 1:1 in 25% ethanol; a tincture at 1:5 in 45% ethanol; and a dry extract at 5 to 7:1 made with 30% to 60% ethanol. A ratio such as 5 to 7:1 means 5 to 7 kg of dried herb went into each kilogram of extract.

German licensed products, the worked examples

• Cystinol long (Schaper & Brümmer) and Cysto Fink Mono (Omega Pharma Deutschland): each capsule holds 424.8 mg of "Echtes Goldrutenkraut" dry extract, 5.0 to 7.1:1, extracted with 30% (m/m) ethanol. That is roughly 2.1 to 3.0 g of dried herb per capsule.

• Stromic: the S. virgaurea dry extract at 5.4:1 used in Schmitt's 1996 study, at 380 mg per dose.

• Goldruten Tropfen (Bioforce AG): a fresh-plant S. virgaurea extract in 64% ethanol, the preparation in the 1992 urine-volume study.

• Urol mono: an extract of giant goldenrod (S. gigantea), the subject of the 1995 rat study.

• Aqualibra (Medice): 180 mg goldenrod dry extract, 4 to 7:1, extracted with water, combined with restharrow and Java tea in each tablet; the species is not stated.

The extract used in the largest human observation (Cystinol long) sits at the EMA's 5 to 7:1 dry extract specification, its stated range running to 7.1:1, and its 424.8 mg capsule falls inside the EMA's 350 to 450 mg single-dose band.

The US worked example: Herb Pharm

Herb Pharm's Goldenrod liquid extract, as listed by the practitioner retailer Fullscript, gives "Goldenrod flowering top (Solidago canadensis)" at 664 mg of extract per 0.7 mL serving, in 49% to 59% organic cane alcohol with water and vegetable glycerin, taken as one squeeze of the dropper in water 2 to 5 times a day. The listing gives no herb-to-solvent ratio, no flavonoid figure and no statement on whether the herb was fresh or dried. Canadian goldenrod is one of the two species the Ph. Eur. "Goldenrod" monograph covers, but the EMA has not assessed it as a medicine, and it lacks leiocarposide.

Other US listings reviewed

• Smallflower's cut goldenrod: the product name and web address say "virguarea," the Latin name field says S. gigantea, and the description says "Solidago spp."

• Mountain Rose Herbs' cut herb and tincture pages each name S. canadensis in one place and S. gigantea in another.

Tea versus extract

Popowski and colleagues (Journal of Ethnopharmacology, 2021) found that an infusion of commercial S. virgaurea herb contained mainly caffeoylquinic acid derivatives (the chlorogenic acid family), flavonoids and some phenylpropanoids. Most of these parent compounds could not cross a Caco-2 gut cell layer, but human and piglet gut bacteria broke them down into smaller phenylpropionic acid derivatives that could. Flavonoid glycosides are extracted best by ethanol of 70% or more, according to the 2020 Biomolecules review, which is above the 30% to 60% used for the licensed dry extracts.

Food Sources

Goldenrod is not a food and supplies no nutrient anyone needs, so this section covers how people are exposed to it. The main routes are herbal tea and tinctures, licensed European capsules and tablets, multi-herb "kidney" and "bladder" teas, and goldenrod honey. Unifloral goldenrod honey is produced in Central Europe; Czigle and colleagues (Plants, 2022) confirmed its botanical origin by pollen analysis in samples from Hungary, Slovakia and Poland and found the Hungarian ones highest in antioxidant activity. Honey carries traces of pollen, which matters only to people with Asteraceae pollen allergy: Fuiano and colleagues (2006) described a 19-year-old woman, skin-test positive to mugwort, ragweed, dandelion and goldenrod pollen, who had anaphylaxis 10 minutes after eating bread and honey; on testing she reacted to a multifloral honey from bees foraging on Compositae, not to a goldenrod honey specifically.

Who Should Take Goldenrod

The group with the most regulatory backing is narrow: adults and adolescents over 12, not pregnant or breastfeeding, with normal heart and kidney function and no daisy-family allergy, who have minor lower urinary symptoms (mild urgency, frequency or burning without fever, flank pain or blood) and want a traditional flushing remedy alongside, not instead of, medical assessment. That is the person the EMA monograph describes, and the supporting evidence is long use plus open observational studies.

A woman with recurrent cystitis who wants to cut antibiotic use has one placebo-controlled trial to point to, but it tested a three-herb tablet (restharrow, Java tea and goldenrod) for 7 days, not goldenrod alone.

A person with kidney stones is relying on Commission E's 1987 indication, which the EMA did not carry forward, and on rat studies of leiocarposide.

A person buying goldenrod for hay fever, a use some US retailers promote, is relying on no human evidence at all, and is buying a member of the same plant family as ragweed, the main late-summer hay fever trigger.

Who Should AVOID or Use Caution

Contraindications

• Allergy to goldenrod or any plant in the Asteraceae (Compositae) family, which includes ragweed, mugwort, chamomile, chrysanthemum, sunflower and echinacea. This is a formal contraindication in the EMA monograph.

• Edema (fluid retention) caused by heart failure or kidney failure, and any condition in which a doctor has told you to limit fluids. The EMA lists "conditions where a reduced fluid intake is recommended, e.g. severe cardiac or renal diseases"; German product information says, in translation, "no flushing therapy for edema due to impaired heart or kidney function."

• Pregnancy and breastfeeding. The EMA does not recommend use because there are no data, and the 2008 assessment report found no reproductive toxicity studies.

• Children under 12, for lack of experience, according to the EMA monograph and German labels.

• Anyone taking a prescription diuretic, unless the prescriber agrees: the EMA states that "concomitant treatment with synthetic diuretics is not recommended."

Use Caution

• Natural rubber latex allergy. Bains and colleagues (Journal of Investigational Allergology and Clinical Immunology, 2010) showed IgE cross-reactivity between goldenrod proteins and Hevea brasiliensis latex in patients with both allergies and concluded that exposure to either may sensitize to the other.

• Known allergic contact dermatitis to Compositae plants. Schätzle and colleagues (Contact Dermatitis, 1998) reported allergic contact dermatitis from goldenrod herb taken by mouth, a systemic reaction rather than a skin-contact one.

• Lithium users. No goldenrod and lithium report was found for this issue, but anything that changes water and salt balance can change lithium levels, and lithium has a narrow safety margin.

• High blood pressure. Some reference databases, RxList among them, caution that goldenrod might cause the body to retain sodium; in rats, goldenrod flavonoid fractions lowered sodium and potassium excretion even as urine volume rose (Chodera and colleagues, Acta Poloniae Pharmaceutica, 1991), although a later rat study found no such electrolyte effect from the flavonoid fraction. No human blood pressure data were found.

• People avoiding alcohol. Tinctures and fluid extracts are 25% to 65% ethanol, and the EMA requires ethanol labeling on them.

• Symptoms that suggest more than a minor complaint: fever, chills, flank or back pain, blood in the urine, or symptoms lasting beyond 5 days. These need a clinician, not more flushing.

Critical Safety Point

The most serious mistake is using goldenrod to treat swelling of the legs or ankles. Goldenrod is often described as a "water pill," and swollen legs look like a problem that a water pill should fix. In heart failure and kidney failure, though, the swelling comes from a heart or kidney that cannot handle the fluid load, and the treatment frequently includes limiting fluids. Flushing therapy does the opposite: it combines a mild diuretic with an instruction to drink 1.5 to 2 liters or more a day. That is why Commission E, the EMA and every German product leaflet reviewed for this issue rule it out for edema of cardiac or renal origin. A herbal "diuretic" does not replace furosemide or spironolactone, and unexplained new swelling, breathlessness when lying flat, or sudden weight gain are reasons to see a doctor promptly, not reasons to buy a tea.

Recommended Dosages

No dose of goldenrod has been established in a controlled trial of goldenrod alone. The figures below are the amounts European regulators allow labels to state for licensed S. virgaurea medicines, based on traditional use; they are not evidence of benefit, and they do not transfer automatically to products made from other species.

Cut herb, as tea

The EMA monograph allows 3 to 5 g of herb as an infusion, 2 to 4 times a day, for adults and adolescents over 12. Commission E gave a daily dose of 6 to 12 g of herb, or equivalent preparations.

Tincture and liquid extract

EMA: tincture (1:5 in 45% ethanol), 0.5 to 2 mL three times a day; liquid extract (1:1 in 25% ethanol), 0.5 to 2 mL three times a day. Herb Pharm's label serving is 0.7 mL, 2 to 5 times a day, but without a stated ratio it cannot be converted into grams of herb or compared with the EMA range.

Dry extract

EMA: 350 to 450 mg of a 5 to 7:1 extract three times a day. Cystinol long and Cysto Fink Mono labels: one 424.8 mg capsule 3 to 4 times a day, with water.

Fluid

Flushing therapy depends on fluid intake. Cystinol long's leaflet asks for 1.5 to 2 liters a day unless heart or circulatory disease rules it out; Aqualibra's asks for at least 2 liters.

Duration

The EMA monograph says goldenrod is traditionally used for 2 to 4 weeks and that persistent symptoms need a doctor. German labels advise seeing a doctor if symptoms last more than 5 days. No controlled study of use beyond a few weeks was found; the one longer open study in the EMA file is described under Research Status.

Timing & Administration

No human pharmacokinetic study of goldenrod was found for this issue, so nothing is known about blood levels, half-life or the effect of food. Product instructions differ: Herb Pharm says "best taken between meals," Cystinol long's leaflet says after meals with about a glass of water, and in the Aqualibra trial patients took tablets at least 1 hour before or after meals and spread plenty of liquid evenly through the day. Because the point of flushing therapy is a steady flow of dilute urine, the fluid matters more than the clock: the regulatory documents tie dosing to drinking enough. Practically, a last dose in the late evening will mean more trips to the toilet at night.

The one compound with timing data is leiocarposide, in rats: Chodera and colleagues (1985) found its diuretic effect began slowly, at around 5 hours, and lasted up to 24 hours, and was about 30% stronger by injection than by mouth. No such data exist for any whole extract in people.

Timeline of Effects

Each time point below comes from a specific study and describes when something was measured, not a schedule to follow.

Urine volume

In 22 healthy volunteers, a 27% rise in daily urine volume was measured over 2 days of Goldruten Tropfen (EMA summary of the unpublished 1992 study).

Symptoms of acute cystitis, three-herb tablet

In the Aqualibra trial, symptom scores separated from placebo after 1 day of treatment and the gap widened by day 7, the end of treatment. Painful urination drove the day 1 difference; urinary frequency only separated by day 7.

Irritable bladder and dysuria, open studies

Assessed at 14 days, about 4 weeks and 5 weeks; without controls, these mark when outcomes were recorded, not when an effect begins.

What counts as a fair trial, and when to stop

The EMA's traditional-use window is 2 to 4 weeks. For acute urinary symptoms the more important limit is shorter: German labels say a doctor should be seen if symptoms continue beyond 5 days, or at once for fever or blood in the urine. Nearly half the placebo group in the Aqualibra trial (49.2% of the evaluable women) needed an antibiotic within 7 days, a reminder that a real infection often does not settle on fluids alone.

Benefits of Taking Goldenrod

The demonstrated benefits are modest and mostly indirect: a 27% rise in urine volume in one small, open, unpublished volunteer study; uncontrolled improvement rates in irritable bladder and dysuria; and a placebo-controlled win in acute cystitis for a tablet in which goldenrod was one of three herbs. Anti-inflammatory, antifungal, stone-preventing and antitumor effects come from rodent and cell studies. In regulatory terms the benefit is "to increase the amount of urine," for minor complaints, as an addition to other care, and that is the only claim a European regulator has accepted.

Potential Negatives & Side Effects

What the regulators list

The EMA monograph lists hypersensitivity reactions and gastrointestinal disorders, frequency unknown. Its 2008 assessment report put hypersensitivity and mild gastrointestinal effects at 0.07% to 0.3% of patients in the studies it reviewed, and recorded only one minor event (heartburn) in the two large post-marketing observations. Cysto Fink Mono's prescribing information lists occasional nausea, heartburn, a feeling of fullness, diarrhea and flatulence, and rare itching, rash and hives. Aqualibra's lists very rare nausea, vomiting, diarrhea, rash and itching, with an instruction not to take it again after a first sign of hypersensitivity.

What pharmacovigilance has collected

The EMA's 2021 review found 28 suspected adverse reaction reports for S. virgaurea in EudraVigilance, including 2 of rash and 2 of diarrhea, and 41 in the WHO's VigiBase between January 1, 2008 and September 3, 2021, and concluded there were "no new safety concerns." The searches used the terms "Solidago virgaurea" and "Goldenrod," and spontaneous reports undercount.

Allergy

Allergic reactions are the most plausible serious harm. Goldenrod is a recognized Compositae allergen: in guinea pig sensitization tests Zeller, de Gols and Hausen (Archives of Dermatological Research, 1985) ranked S. virgaurea a medium sensitizer, alongside giant ragweed; Lundh and colleagues (Contact Dermatitis, 2006) documented contact allergy to herbal teas made from Asteraceae plants; and the 1998 Schätzle case showed that dermatitis can follow swallowing the herb. The cross-reactivity with latex reported in 2010 adds a non-obvious group at risk.

Side effects of flushing itself

More urine means more trips to the toilet, including at night, which weighs most on older adults with continence problems.

Delayed treatment

The indirect risk is that a woman with a true bacterial cystitis, or a man with prostatitis, treats it with tea for a week. The Aqualibra trial excluded anyone with signs of complicated infection or kidney involvement, and its own placebo arm shows how often antibiotics were still needed.

Deficiency Symptoms

What goldenrod addresses

No deficiency. Nothing in human physiology depends on leiocarposide, virgaureasaponins or goldenrod's flavonoid profile, and no blood test measures goldenrod "status." Goldenrod is taken for a symptom (minor lower urinary discomfort) and for an effect (more urine), not to correct a shortfall.

Bottom line

There is no goldenrod deficiency state. The measurements that matter for a goldenrod user belong to the conditions around it: a urine culture when infection is suspected, and kidney function, sodium and potassium for anyone with heart or kidney disease or on a diuretic, where flushing therapy should not be started in the first place without a doctor.

Toxicity Symptoms

At high intake

No human poisoning from any Solidago species taken by mouth was found in the medical literature for this issue, and the EMA monograph states that no case of overdose has been reported. The animal data are thin. The acute oral LD50 of isolated leiocarposide in rats is 1.55 g/kg, the only acute toxicity figure in the EMA's 2008 assessment report. Koshovyi and colleagues (Pharmaceutics, 2025) classed dry extracts of Canadian goldenrod as practically non-toxic, with an LD50 above 5,000 mg/kg (toxicity class V). The fixed combination Phytodolor showed no effect on fertility, mating or litter size in two reproductive studies, a result for a three-plant mixture, not for goldenrod. For S. virgaurea itself, the EMA found no repeated-dose, genotoxicity, carcinogenicity or reproductive toxicity data, and said that because of the missing mutagenicity data its inclusion on the EU's Community list of herbal substances for traditional use "cannot be considered."

Signs to reduce or stop

Stop at once and seek urgent care for swelling of the lips, tongue or throat, wheezing, hives spreading over the body, or faintness, which suggest a serious allergic reaction. Stop and see a clinician for a new rash or itching (including dermatitis away from where anything touched the skin), persistent nausea, heartburn or diarrhea, and for any sign the urinary problem is worsening: fever, chills, flank pain or blood in the urine. Anyone with heart or kidney disease who notices rising ankle swelling, breathlessness or rapid weight gain should stop and be seen. A lithium user who develops tremor, unsteadiness, confusion, vomiting or diarrhea needs a lithium level checked.

General note

The likeliest toxic exposure in a goldenrod product may not come from goldenrod. The German medpharm monograph warns that wild-collected goldenrod could be adulterated with ragwort and groundsel (Senecio species), which contain liver-damaging pyrrolizidine alkaloids; see Quality, Testing & Adulteration.

How Goldenrod Works

Diuretic or aquaretic: the unsettled question

Synthetic diuretics such as furosemide make the kidney excrete more salt, and water follows. An "aquaretic" would increase water output with little extra salt loss. Goldenrod is often described as aquaretic, but the rat data conflict. Chodera and colleagues (1991) gave rats flavonoid fractions from S. virgaurea, S. gigantea and two varieties of S. canadensis by mouth and recorded 57% to 88% more overnight urine with less sodium and potassium excreted, and, for two of the four fractions, more calcium. Kaspers and colleagues, as summarized in the 2020 Biomolecules review, later found no effect from the flavonoid fraction, and instead found that hydroxycinnamic acid (100 mg/kg) and saponin (25 to 100 mg/kg) fractions acted comparably to furosemide, increasing sodium and potassium excretion. The two results are hard to reconcile, and neither tells us what a cup of tea does in a person.

Neutral endopeptidase

The proposed flavonoid mechanism is inhibition of neutral endopeptidase, the enzyme that breaks down the body's natriuretic peptides; slower breakdown would raise those peptides and with them salt and water excretion. This rests on laboratory enzyme work and has not been demonstrated in people.

Leiocarposide

The S. virgaurea phenolic glycoside leiocarposide raised 24-hour urine volume in rats by 70% at 25 mg/kg by injection, against 125% for furosemide at 6 mg/kg, in the EMA's summary (Chodera and colleagues, 1985); its sugar-free core, leiocarpic acid, had none. At 25 mg/kg by mouth for 6 weeks it slowed the growth of human urinary stones implanted in rat bladders. Leiocarposide is the clearest chemical reason to treat S. virgaurea as a different herb from S. canadensis and S. gigantea, which lack it.

Spasm and inflammation

Goldenrod extracts relax isolated guinea pig intestine and, in a combination product, rat bladder strips, though one ethanol extract managed less than 15% of the effect of papaverine. Anti-inflammatory activity in rat edema models has been attributed to several fractions: a triterpene saponin fraction given intravenously at 1.25 to 2.5 mg/kg (Jacker and colleagues, 1981), 3,4,5-tri-O-caffeoylquinic acid (88% of the effect of indomethacin), and whole giant goldenrod extract at a dose matching diclofenac (Leuschner, 1995). Leiocarposide was weak by comparison: 27% edema reduction at 5 hours against 54% for phenylbutazone (Metzner and colleagues, 1984).

Antimicrobial and anti-adhesive effects

S. virgaurea extracts had a broader antimicrobial range in culture than giant or Canadian goldenrod extracts (Brantner, 1999, cited by the EMA). Saponins inhibit Candida, with the deacylated bidesmosidic saponins most active. Whether urine after an oral dose contains anything at an antibacterial concentration has not been measured.

What reaches the body

Most parent compounds in goldenrod tea do not cross the intestinal wall intact in cell models; gut bacteria convert them into small phenolic acids that do (Popowski and colleagues, 2021). Which of those metabolites, if any, act on the kidney or bladder is unknown.

Synergistic Supplements

Water is the partner that matters

Every licensed goldenrod product is designed around drinking more, and no study has separated the herb's effect from the water's.

Classic European urological combinations

Goldenrod rarely travels alone in Europe. Aqualibra pairs it with restharrow root and Java tea, the only combination with a placebo-controlled win in acute cystitis. The products in the two Italian studies above pair it with Java tea and birch leaf (Cistimev and Cistimev Plus). Fluxonorm, a food supplement studied in Italy, combines goldenrod with Phyllanthus niruri, Epilobium angustifolium, Peumus boldus and Ononis spinosa; an uncontrolled study of 30 men with benign prostatic hyperplasia added one 1,200 mg tablet daily to standard care for 30 days and reported better urinary flow (Orlando and colleagues, European Review for Medical and Pharmacological Sciences, 2021). Fixed combinations with bearberry (uva ursi) leaf also exist, according to the medpharm monograph, and Herb Pharm lists a Goldenrod Horsetail Compound in the US. In none of these has the goldenrod share been tested on its own.

What not to stack

Adding goldenrod to other herbs sold as "water pills," such as juniper, horsetail, nettle leaf or Java tea products, multiplies the fluid effect without adding evidence, and is exactly the stacking that matters for someone on lithium or a prescription diuretic. Combining goldenrod with chamomile, echinacea or other daisy-family herbs increases the chance of an Asteraceae reaction in a sensitized person.

Interactions & What NOT to Take

No human drug interaction study of any Solidago preparation was found for this issue. The EMA monograph records no reported interactions, although its 2008 assessment report noted that "some interactions are possible due to influence on CYP3A4 genes expression," which no human study has tested. The cautions below come from goldenrod's intended effect, a regulatory warning, and laboratory work, and are named drug by drug.

Prescription diuretics

Furosemide, bumetanide, torsemide, hydrochlorothiazide, chlorthalidone, chlorothiazide, indapamide, spironolactone and eplerenone. The EMA states that "concomitant treatment with synthetic diuretics is not recommended." RxList rates the goldenrod and "water pill" combination minor; the plausible concerns, greatest in older adults, are extra fluid loss, low blood pressure on standing and electrolyte shifts. The people most likely to be on these drugs, those with heart failure or kidney disease, are the people for whom flushing therapy is contraindicated anyway.

Lithium

Lithium carbonate and lithium citrate. No case report was found. Lithium levels are sensitive to changes in fluid and sodium balance, and a herb taken specifically to change urine output is a reasonable thing to clear with the prescriber, with a lithium level checked if it is started.

Antibiotics for urinary infection

Ciprofloxacin and amikacin. In a laboratory study, Wojnicz and colleagues (Pharmaceutics, 2021) found that an S. virgaurea extract, while inhibiting uropathogenic E. coli on its own, weakened the antibacterial activity of both antibiotics when combined with them and shortened their post-antibiotic effect; by 72 hours the extract and antibiotic mixtures produced more biofilm than untreated controls. This is a test-tube finding with no clinical follow-up, but it argues against assuming that goldenrod plus an antibiotic is better than the antibiotic alone.

Sacubitril and valsartan (Entresto)

A theoretical overlap only: sacubitril works by inhibiting neutral endopeptidase, the same enzyme goldenrod flavonoids inhibit in laboratory assays. No study links the two, and anyone on this heart failure drug is already in the group for whom flushing therapy is contraindicated.

P-glycoprotein substrates

A 2026 cell study (Gębarowska and colleagues, Molecules) reported increased retention of a test dye in drug-resistant cancer cells exposed to a giant goldenrod extract, suggesting possible inhibition of the P-glycoprotein drug pump. No human data exist, and whether this matters for P-glycoprotein drugs such as digoxin is unknown.

Quality, Testing & Adulteration

Species substitution is built into the trade

The German medpharm monograph (2003) states that herb from S. gigantea and S. canadensis is traded as a substitute for true European goldenrod despite differences in activity. In Europe that is legal as long as the label says which herb it is, because each has its own pharmacopoeial monograph. On US retail pages it shows up as contradiction: Smallflower's cut goldenrod is named "virguarea" in its title and S. gigantea in its Latin field; Mountain Rose Herbs' goldenrod pages name both S. canadensis and S. gigantea.

Ragwort and groundsel, the toxic adulterant risk

The same monograph warns that wild-collected goldenrod could be adulterated with Senecio species (ragwort and groundsel), which contain pyrrolizidine alkaloids that damage the liver. The EU caps the sum of 21 named pyrrolizidine alkaloids (plus 14 that co-elute with them) at 200 micrograms per kg in dried herbal infusions and 400 micrograms per kg in herbal food supplements, limits first set by Commission Regulation (EU) 2020/2040. No US limit for these alkaloids in supplements was found for this issue. No published survey of pyrrolizidine alkaloids in goldenrod products was located either, so the size of the risk is unmeasured.

What the pharmacopoeial tests do and do not prove

A Ph. Eur. total flavonoid result "expressed as hyperoside" confirms a flavonoid level, not a species. Because S. virgaurea is capped at 1.5% and the North American species start at 2.5%, a European goldenrod lot testing at 3% should prompt the question of whether it is really S. virgaurea. Leiocarposide is the more useful species marker: present in European goldenrod, absent from Canadian and giant goldenrod, and measurable by HPLC. Individual flavonoid patterns also differ by species (rutin-rich Canadian goldenrod, hyperoside and quercitrin in giant goldenrod, in Zekič and colleagues' 2021 samples).

Third-party testing

No goldenrod product with a USP Verified, NSF Certified or ConsumerLab seal was found for this issue, and no USP dietary supplement monograph for goldenrod was located. In Germany and Poland the licensed medicines are made to Ph. Eur. specifications under pharmaceutical manufacturing rules, which is the strongest quality assurance available for this herb, but those products are not sold in US stores.

How to check a bottle yourself

Read the Latin name first. "Solidago virgaurea" matches the European approval; "Solidago canadensis" or "Solidago gigantea" is a legitimate pharmacopoeial herb but a different one; "Solidago spp." or a page that gives two different species tells you the seller has not pinned it down. Then look for the plant part (flowering tops), the extract ratio and solvent for any liquid or capsule, and a lot number. If you ask the seller for a certificate of analysis, a useful one names the species and the identity method (thin layer chromatography or HPLC, ideally showing leiocarposide for a product sold as S. virgaurea), reports total flavonoids as hyperoside with the Ph. Eur. range it was judged against, and gives a pyrrolizidine alkaloid result in micrograms per kg alongside the EU limit. A seller who cannot supply a pyrrolizidine result for wild-harvested herb has not looked for the most dangerous contaminant.

Special Considerations

Goldenrod and hay fever: the record

Goldenrod is widely blamed for late-summer hay fever because it blooms conspicuously at the same time as ragweed (Ambrosia), the wind-pollinated plant that is the main late-summer culprit. Goldenrod is insect-pollinated, and as Illinois Extension put it in 2022, it "produces pollen grains too heavy to be transported by wind." That does not make its pollen harmless at close range. De Jong and colleagues (Allergy, 1998) described 14 consecutive patients, most of them flower-industry workers, with rhinitis, asthma or hives from handling flowers, and found extensive cross-sensitization among Compositae pollens including solidago. Perrick and colleagues (Journal of Allergy and Clinical Immunology, 1991) found antigens in goldenrod pollen that cross-react with short ragweed, at lower potency than giant ragweed or cocklebur. A 2005 Sarajevo allergy survey included S. gigantea pollen in its weed test mix. For a person with ragweed or mugwort allergy, the useful rule is that goldenrod in a vase or a tea is a plausible trigger, while goldenrod in a distant field is not the reason for their sneezing.

Regulatory status

• European Union: EMA/HMPC community herbal monograph on Solidago virgaurea L., herba (EMEA/HMPC/285758/2007), adopted September 4, 2008, traditional use; periodic review adopted September 22, 2021, no revision. Seven goldenrod preparations were on the EU market at that review, five in Germany and two in Poland.

• Germany: Commission E monograph published in the Bundesanzeiger (no. 193a) on October 15, 1987, with a correction dated March 13, 1990, covering both true goldenrod (S. virgaurea) and goldenrod herb from S. gigantea, S. canadensis and their hybrids, for flushing in inflammatory urinary tract disease, urinary stones and kidney gravel, at 6 to 12 g of herb a day. German products such as Cysto Fink Mono still carry the stone and gravel indications that the later EMA monograph omits.

• ESCOP, the European scientific cooperative on phytotherapy, also publishes a Solidaginis virgaureae herba monograph.

• United States: sold as a dietary supplement under DSHEA, with no FDA review of safety, efficacy or species.

Research Status & Evidence Quality

Tier 1, placebo-controlled trial of a combination

The 200-woman Aqualibra cystitis trial, and Phytodolor's placebo-controlled and NSAID-controlled trials in rheumatic pain. Neither isolates goldenrod.

Tier 2, other controlled combination studies

The catheter, stent and prophylaxis studies described under Primary Functions & Benefits (83, 60 and 164 patients), each with a different multi-herb product and none placebo-controlled.

Tier 3, open studies of goldenrod-only products

The volunteer urine study, Schmitt's dysuria study and the Cystinol long observation described above, plus a 1992 Bioforce study in which 53 patients aged 6 to 83 with urinary tract inflammation took Goldruten Tropfen for up to a year, with clinical improvement reported in 65.4%. None had a concurrent control group, and neither 1992 study appears to have been published.

Tier 4, animal and laboratory work

Diuresis, stone growth, spasm, inflammation and antimicrobial effects in rats, guinea pig tissue and cultures, with conflicting results on which fraction drives diuresis.

Research Limitations

The clinical file is dominated by post-marketing observations of commercial products from the 1990s, two of them unpublished company studies, and the EMA's assessor could not judge their quality. Almost every human study used S. virgaurea, while the Ph. Eur. "Goldenrod" monograph and much of the US market use S. canadensis or S. gigantea, which lack leiocarposide and have essentially no human data of their own. No human pharmacokinetic or drug interaction study, and no reproductive toxicity or genotoxicity study, was found. The most-cited dysuria study is reported with a tenfold difference in its sample size between sources.

Summary & Key Takeaways

Bottom Line

Goldenrod's European standing is a traditional-use approval for one species, S. virgaurea, to increase urine output as an add-on for minor urinary complaints, granted because of long use rather than trial evidence. The best controlled result belongs to a three-herb tablet in acute cystitis. Several US products reviewed for this issue contain Canadian or giant goldenrod, recognized in their own pharmacopoeial monograph but chemically distinct and essentially unstudied in people, and some US listings cannot agree with themselves on which species they sell.

Key Safety Points

• Do not use goldenrod for swelling caused by heart or kidney failure, or if a doctor has told you to restrict fluids.

• Avoid it with an allergy to ragweed, mugwort, chamomile or any daisy-family plant, and be cautious with a latex allergy.

• Not recommended in pregnancy, while breastfeeding, or for children under 12.

• Do not combine with prescription diuretics, and clear it with the prescriber if you take lithium.

• Fever, flank pain, blood in the urine, or symptoms lasting beyond 5 days need a clinician, not more tea.

• Check the Latin name on the label; S. virgaurea, S. canadensis and S. gigantea are different herbs.

Special Note

The fix for goldenrod's label problem is simple and costs nothing: print one species, the plant part, and the extract ratio. European medicines already do. Until US sellers do the same, a goldenrod buyer cannot know whether the bottle matches the herb that the European approval, and nearly all of the human research, describes.

Forwarded this, or reading it on the web? to get the next breakdown.

Researched and drafted with AI assistance. Every claim verified against primary sources and human-reviewed before publication. Last reviewed: November 2, 2026. Corrections: reply to any issue.

This issue is for education and is not medical advice. If you take any prescription medicine, have a diagnosed condition, or are pregnant or breastfeeding, talk to a clinician before taking goldenrod or changing anything you already take.